Interleukin-12 as an in situ cancer vaccine component: a review

[1]  R. Weissleder,et al.  Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. , 2022, Immunity.

[2]  D. Weiner,et al.  Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors , 2021, Journal for ImmunoTherapy of Cancer.

[3]  P. Libby,et al.  Interleukins in cancer: from biology to therapy , 2021, Nature Reviews Cancer.

[4]  I. Melero,et al.  Intratumoural administration and tumour tissue targeting of cancer immunotherapies , 2021, Nature Reviews Clinical Oncology.

[5]  Yu Seong Lee,et al.  Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1 , 2020, Gene Therapy.

[6]  D. Zaharoff,et al.  Localized Interleukin-12 for Cancer Immunotherapy , 2020, Frontiers in Immunology.

[7]  J. Lapointe,et al.  Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment , 2020, Clinical Cancer Research.

[8]  Amy K. Erbe,et al.  In situ Vaccine Plus Checkpoint Blockade Induces Memory Humoral Response , 2020, Frontiers in Immunology.

[9]  G. Rao,et al.  Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma. , 2020 .

[10]  B. Fox,et al.  Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma , 2020, Clinical Cancer Research.

[11]  A. Villa,et al.  The antibody‐based delivery of interleukin‐12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors , 2020, International journal of cancer.

[12]  J. Hubbell,et al.  Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours , 2020, Nature Biomedical Engineering.

[13]  R. Garje,et al.  Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence , 2020, Cancers.

[14]  B. Fox,et al.  Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Y. Arai,et al.  Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade , 2020, Science Translational Medicine.

[16]  Jian Ye,et al.  Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment , 2019, Cell reports.

[17]  P. Wen,et al.  Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial , 2019, Science Translational Medicine.

[18]  Amanda R. Campbell,et al.  A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma , 2019, Clinical Cancer Research.

[19]  Ralph Weissleder,et al.  Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12 , 2018, Immunity.

[20]  J. Schlom,et al.  First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors , 2018, Clinical Cancer Research.

[21]  M. Tao,et al.  Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment , 2018, Oncoimmunology.

[22]  D. Czerwinski,et al.  Eradication of spontaneous malignancy by local immunotherapy , 2018, Science Translational Medicine.

[23]  R. Martuza,et al.  Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. , 2017, Cancer cell.

[24]  G. Deplanque,et al.  Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow “in situ tumor vaccination”? , 2017, Cancer Immunology, Immunotherapy.

[25]  J. Schlom,et al.  Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody , 2017, Oncotarget.

[26]  P. Harari,et al.  In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. , 2016, Cancer research.

[27]  P. Selvaraj,et al.  Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12 , 2016, Human vaccines & immunotherapeutics.

[28]  S. Demaria,et al.  Role of Local Radiation Therapy in Cancer Immunotherapy. , 2015, JAMA oncology.

[29]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[30]  H. Grönlund,et al.  Evaluation of safety and efficacy as an adjuvant for the chitosan-based vaccine delivery vehicle ViscoGel in a single-blind randomised Phase I/IIa clinical trial. , 2014, Vaccine.

[31]  B. Becher,et al.  New insights into IL-12-mediated tumor suppression , 2014, Cell Death and Differentiation.

[32]  C. Muller,et al.  A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study. , 2014, Gynecologic oncology.

[33]  H. Kohrt,et al.  Intratumoral Immunization: A New Paradigm for Cancer Therapy , 2014, Clinical Cancer Research.

[34]  J. Schlom,et al.  The immunocytokine NHS-IL12 as a potential cancer therapeutic , 2014, Oncotarget.

[35]  M. Jakóbisiak,et al.  Interleukin 12: still a promising candidate for tumor immunotherapy? , 2014, Cancer Immunology, Immunotherapy.

[36]  B. Becher,et al.  Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection , 2013, The Journal of experimental medicine.

[37]  M. Jakóbisiak,et al.  Synergistic antitumor effect of JAWSII dendritic cells and interleukin 12 in a melanoma mouse model. , 2013, Oncology reports.

[38]  S. Gillies,et al.  Current and Potential Uses of Immunocytokines as Cancer Immunotherapy , 2012, Antibodies.

[39]  J. Schlom,et al.  Intratumoral Immunotherapy of Established Solid Tumors With Chitosan/IL-12 , 2010, Journal of immunotherapy.

[40]  M. Barnes,et al.  Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer , 2010, Gene Therapy.

[41]  J. Bartek,et al.  The DNA-damage response in human biology and disease , 2009, Nature.

[42]  V. Pistoia,et al.  Interleukin-12 receptor beta2: from cytokine receptor to gatekeeper gene in human B-cell malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. J. Kelleher,et al.  IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. , 2009, Clinical immunology.

[44]  J. Prieto,et al.  Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  A. Weinberg,et al.  IL-12 Is Required for Anti-OX40-Mediated CD4 T Cell Survival , 2008, The Journal of Immunology.

[46]  J. Weiss,et al.  Immunotherapy of cancer by IL-12-based cytokine combinations , 2007, Expert opinion on biological therapy.

[47]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[48]  Huan Yang,et al.  Combination nonviral murine interleukin 2 and interleukin 12 gene therapy and radiotherapy for head and neck squamous cell carcinoma. , 2005, Archives of otolaryngology--head & neck surgery.

[49]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[50]  J. Norton,et al.  Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. , 2002, Cancer research.

[51]  S. Gillies,et al.  Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer , 2002, Cancer Immunology, Immunotherapy.

[52]  C. Halin,et al.  Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature , 2002, Nature Biotechnology.

[53]  N. Hayashi,et al.  Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. , 2001, Cancer research.

[54]  M. Sabel,et al.  In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. , 2000, Cancer research.

[55]  S. Ostrand-Rosenberg,et al.  Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γ , 2000, Cancer Immunology, Immunotherapy.

[56]  D. Mahvi,et al.  Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[57]  N. Yang,et al.  Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. , 1999, Journal of immunotherapy.

[58]  C. Uyttenhove,et al.  Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide‐pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin‐12 , 1999, International journal of cancer.

[59]  B. Car,et al.  The Toxicology of Interleukin-12: A Review , 1999, Toxicologic pathology.

[60]  P. Kalinski,et al.  High-level IL-12 production by human dendritic cells requires two signals. , 1998, International immunology.

[61]  S. Gillies,et al.  Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. , 1998, Journal of immunology.

[62]  L. Schwartz,et al.  Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[63]  J. Norton,et al.  Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. , 1998, Journal of immunology.

[64]  J. Leonard,et al.  Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production , 1997 .

[65]  N. Yang,et al.  Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. , 1997, Human gene therapy.

[66]  N. Yang,et al.  Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[67]  M. Colombo,et al.  Amount of interleukin 12 available at the tumor site is critical for tumor regression. , 1996, Cancer research.

[68]  M. Colombo,et al.  Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. , 1996, Cancer research.

[69]  J Cohen,et al.  IL-12 Deaths: Explanation and a Puzzle , 1995, Science.

[70]  Yao-Tseng Chen,et al.  Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[71]  J. Orange,et al.  Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids , 1995, The Journal of experimental medicine.

[72]  R. Schreiber,et al.  Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. , 1994, Journal of immunology.

[73]  G. Trinchieri,et al.  Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells , 1994, The Journal of experimental medicine.

[74]  G. Trinchieri,et al.  Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells , 1993, The Journal of experimental medicine.

[75]  I. Lubensky,et al.  Combination interleukin-2 and interleukin-12 induces severe gastrointestinal toxicity and epithelial cell apoptosis in mice. , 2002, Cytokine.

[76]  J. Wigginton,et al.  Antitumor activity of interleukin 12 in preclinical models , 1996, Cancer Chemotherapy and Pharmacology.

[77]  G. Trinchieri.  Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. , 1995, Annual review of immunology.